Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Erin Bohula
Dr Erin Bohula, MD, DPhil is an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor of Medicine at Harvard Medical School, and an Investigator at the TIMI Study Group. Dr Bohula research interests include the interplay of obesity, metabolic health and cardiovascular disease, evaluation of novel biomarkers and the application of innovative technologies for… View more
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Dr. Midtbø is senior researcher at The centre for research on heart disease in women at the University of Bergen (https://www.uib.no/en/femaleheart) and MD at the Department of Heart Disease, Haukeland University Hospital, Norway. Her research focuses on heart disease in patients with rheumatic and autoimmune diseases, obesity and cardiac disease in women. Dr Helga Midtbø is on the Editorial… View more
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Kidney Metabolic
Job title: Professor of Medicine and Pharmacology and Chief of the Section of Endocrinology, Diabetes, and Metabolism
Research Area(s) / Expertise: Job title: Head of Pathology
Prof Carel le Roux isHead of Pathology atUniversity College Dublin, Dublin, IE. He graduated from medical school in Pretoria South Africa, completed his Senior House Officer training at Barts and The London Hospital, his SpR training in metabolic medicine at the Hammersmith Hospitals and his PhD at Imperial College London. Working within the Diabetes Complications Research Centre and the… View more
George Abdelfady Nashed
Job title: Professor of General Laparoscopic and Bariatric Surgery, Kasr Al-aini-Cairo University, Egypt
Prof George Abdelfady Nashed is a Professor of General Laparoscopic and Bariatric Surgery, in the Faculty of Medicine at Kasr Al-aini-Cairo University, Egypt. He completed his Masters Degree in General Surgery, and Doctoral Degree of General and Laparoscopic Surgery. Prof Nashed is a member of the Royal College of Surgeons (UK), the European Association of Endoscopic Surgery (EAES), the… View more
AHA 24: 3 Trials That Will Change My Practice
Author(s): Michelle Kittleson Added: 1 year ago
AHA Conference 2024 - In this highlights video from AHA 2024, Dr Michelle Kittleson (Cedars-Sinai California Heart Center, US) offers a concise and insightful summary of the most influential late-breaking trials presented at the conference. Dr Kittleson discusses the pivotal studies poised to impact clinical practice and enhance patient outcomes in heart failure care.Trials covered in detail… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Lawrence A Leiter
Research Area(s) / Expertise: Job title: Professor
Dr Lawrence A Leiter is Director of the Lipid Clinic; Associate Director of the Clinical Nutrition and Risk Factor Modification Centre; and Associate Scientist, Li Ka Shing Knowledge Institute at St Michael’s Hospital in Toronto, Canada. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.Dr Leiter is a Past-President of the Canadian Society of… View more
Semaglutide May Aid Vascular Repair in High-Risk Patients
Added: 4 weeks ago Source:  Radcliffe CVRM
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known to reduce major atherosclerotic cardiovascular events, but the full extent of their mechanisms is still being explored. The SEMA-VR CardioLink-15 trial investigated whether semaglutide affects the levels of circulating vascular regenerative (VR) cells, which are involved in vessel repair and may modulate atherothrombotic risk.¹… View more

Cardiovascular Kidney Metabolic